Mesoblast Taps Regeneron Exec to Lead Clinical Expansion
Event summary
- Dr. Teresa Montagut joins Mesoblast as Head of Clinical Development and Medical Affairs on March 11, 2026.
- Montagut previously led early pipeline studies in oncology and medical affairs at Regeneron.
- She will focus on expanding indications for Ryoncil® and advancing Mesoblast’s cell therapy pipeline.
- Montagut brings experience from Novartis, Genentech, and Atara Biotherapeutics in cancer immunotherapy.
The big picture
Mesoblast’s appointment of Dr. Teresa Montagut underscores its push to expand the clinical applications of its FDA-approved cell therapy, Ryoncil®, beyond pediatric acute graft versus host disease (aGvHD). The move aligns with broader industry trends toward precision medicine and the growing demand for off-the-shelf cellular therapies. Montagut’s background in oncology and medical affairs suggests Mesoblast is prioritizing strategic collaborations to broaden its pipeline and commercial reach.
What we're watching
- Pipeline Expansion
- How quickly Montagut can accelerate clinical trials for Ryoncil® in new inflammatory conditions.
- Strategic Partnerships
- Whether Mesoblast can leverage Montagut’s industry connections to forge new collaborations.
- Regulatory Approvals
- The pace at which Mesoblast can secure additional FDA approvals for its cell therapy products.
Related topics